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Background: Autoantibodies against bactericidal permeability increasing protein (BPI-ANCA) are frequently present in cystic fibrosis
patients and have been reported to be associated to colonization with Pseudomonas (P) aeruginosa and lung damage. In the present study, we
investigated BPI-ANCA as a prognostic marker and its relation to P. aeruginosa colonization and lung function.
Methods: BPI-ANCA, measured by ELISA, was examined relative to lung function and microbiological findings. The prognostic value of
BPI-ANCA was assessed in 46 adult patients followed for 1.2–8.9 years. The cross-sectional investigation was performed in 366 patients
(age 0.5–55).
Results: The presence of BPI-ANCA predicted poor prognosis. An adverse outcome occurred in 15/28 BPI-ANCA positive patients and in
2/18 BPI-ANCA negative patients ( p=0.01). This result remained valid when the patients were stratified according to lung function
( p=0.03). Findings of BPI-ANCA were correlated to P. aeruginosa colonization and lung damage. Development of BPI-ANCA occurred
after colonization with P. aeruginosa. All colonized patients did not develop BPI-ANCA. The BPI-ANCA levels were fairly stable during the
disease course, but decreased significantly following lung transplantation.
Conclusion: BPI-ANCA responses follow colonization with P. aeruginosa and may be predictive for lung damage.
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The lack of reliable prognostic factors for assessment of
long-term lung function is a well-known problem in cystic
fibrosis (CF) patients [1]. CF is characterized by excessive☆ In part previously presented at the Seventeenth Annual North American
Cystic Fibrosis Conference (2003) in Anaheim, CA, USA (1).
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doi:10.1016/j.jcf.2006.10.005mucus production and chronic bacterial colonization of the
airways, ultimately leading to respiratory insufficiency.
Colonization with Pseudomonas (P) aeruginosa is known
to promote lung damage [2,3]. Nevertheless, some patients
carry P. aeruginosa for years with preserved lung function,
while other patients show rapid deterioration.
The genetic background of cystic fibrosis (CF) is amutation
in the gene of an ion channel called the CF transmembrane
conductance regulator (CFTR) [4]. More than 1000 mutations
have been described, resulting in varying functionality of the
CFTR. However, the severity of the lung disease is noted by Elsevier B.V. All rights reserved.
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mutations that are associated with a mild disease [1,2].
Autoantibodies against bactericidal permeability increasing
protein (BPI) are frequently present inCF [5–10]. BPI is one of
the most potent antimicrobial factors of the innate defence
repertoire against Gram-negative bacteria. BPI mainly origi-
nates from the azurophilic granules of polymorph nuclear
leukocytes [11,12]. Antibodies against such proteins are called
antineutrophil cytoplasmic antibodies (ANCA), and they are
well-established markers for the diagnosis and disease activity
of systemic vasculitides [13]. BPI-ANCA is known to occur in
conjunction withP. aeruginosa colonization in CF, but has not
previously been examined as a prognostic factor. BPI-ANCA
also occurs in other diseases with Gram-negative bacterial
colonization such as diffuse panbronchiolitis, bronchiectasis
and in inflammatory bowel disease [14–18]. In CF, BPI-
ANCA has not been found in patients with Gram-positive
colonization only. Gram-negative bacteria other than P.
aeruginosa, such as Burkholderia cepacia are too rare in the
populations studied to be evaluated concerning their relation to
BPI-ANCA (unpublished data).
A previous study from our group suggested that the
presence of BPI-ANCA is strongly correlated to colonization
with P. aeruginosa. We also found that the P. aeruginosa
colonized patients with the highest levels of BPI-ANCA had
the most severe lung damage [9]. This implied that BPI-
ANCA could be a predictor of poor prognosis in CF.
The aims of the present study were to evaluate BPI-
ANCA as a long-term prognostic marker and to confirm the
association between P. aeruginosa colonization, lung
damage and the presence of BPI-ANCA. This was done in
two independent patient cohorts, one Swedish and one
Danish. We also wanted to establish the temporal relation-
ship between P. aeruginosa colonization and BPI-ANCA
responses, in order to elucidate a course of events involved in
development of lung damage in CF.
2. Patients and methods
2.1. Patients
The prognostic value of BPI-ANCAwas determined by a
prospective study of 46 Swedish patients presented in anTable 1












A 55 84 34 44
B 18 85 20 42
C 12 83 26 33
D 15 86 17 32
Lung functions, BPI-ANCA levels and presence of P. aeruginosa colonization are
CFTR genotype: A, homozygosity for ΔF508; B, severe/severe mutation; C, one o
groups are further explained in the Methods section. No significant differences in th
or the Chi-squared test for independence).earlier report [9]. Six patients were lost to follow-up, out of
whom five had moved and one had died from cancer of the
colon. Thus, data from 40 patients were available at the time
of the present study (1.2–8.9 years follow-up). At inclusion,
BPI-ANCAwas positive in 25 of these patients (median age
25, range 18–36). Their median lung function was FEV1%
pred 58% (range 24–95%). BPI-ANCA was negative in 15
patients (median age 22, range 19–43). In this group the
median lung function was FEV1%pred 80% (range 37–
113%).
In the cross-sectional part of the study, all patients with
verified CF at the CF centres of Lund University Hospital,
Sweden, and Rigshospitalet, Copenhagen, Denmark, were
asked to participate. Approval was obtained by the
research ethics committees of the Universities of Lund
and Copenhagen. All patients were genotyped with regard
to CFTR mutations (Department of Clinical Genetics in
Lund or Department of Clinical Genetics in Copenhagen).
The results from each centre are presented separately, as
the methods for measuring lung function and the
definitions of chronic P. aeruginosa colonization differ.
In Lund, informed consent and necessary study data were
obtained from 129 patients, 64 females and 65 males. The
median age of the patients was 19.5 years (range 2.0–
53.5). Lung transplantation had been performed in 8 of the
patients. In Copenhagen informed consent and necessary
study data were obtained from 237 patients, 118 females
and 119 males. The median age of the patients was
19.7 years (range 0.5–54.0). Lung transplantation had been
performed in 13 of the patients. The patients were
subdivided into groups according to CFTR genotype
according to previously published criteria [2–19]: A,
homozygosity for ΔF508; B, severe/severe mutation, i.e.
one class I, class II or class III mutation on each allele
including heterozygosity for ΔF508; C, one or two
missense mutations, i.e. class IV or V mutations; D, one
or two unknown mutations. No significant differences in
lung function, bacterial colonization or BPI-ANCA level
were seen between the genotype groups (Table 1). After
inclusion, the Swedish patients were followed prospec-
tively with new serum samples for BPI-ANCA with
intervals of six to twelve months, and clinical data were









73 79 25 40
13 79 23 40
6 86 12 21
8 83 29 32
presented for each group.
r two missense mutations; D, one or two unknown mutations. The genotype
e median values or percentage of patients were found (the Kruskal-Wallis test
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Pulmonary function was examined with spirometry
according to the American Thoracic Society guidelines
[20]. Forced expiratory volume in 1 second (FEV1) was
chosen as a measure of lung function, as this is a lung
function parameter that closely correlates with prognosis in
CF [21]. In the Danish patients, FEV1 was measured at each
visit in out patient clinic, and the mean values from one year
of measurements were used. The results were expressed as a
proportion of the predicted values (FEV1%pred) based on
height, age, and gender. In children, FEV1%pred were
calculated according to Solymar et al. [22] and in adults over
the age of 18 according to Quanjer [23]. In patients who
reached 18 years of age during the study period, all FEV1%
pred-values were calculated according to Solymar. Normal
lung function was defined as FEV1%pred more than 80%.
FEV1%pred values between 50% and 80% were considered
as moderate lung damage and below 50% the lung damage
was considered severe. In the long-time follow up study, a
composite endpoint for severe adverse outcome was defined
as:
• reaching endpoint, which was defined as lung transplan-
tation or death
• reaching FEV1%pred below 25%
• loosing more than 2.8% in FEV1%pred per year. This was
based on the median loss of FEV1%pred in the cohort,
which was 1.4% per year. Thus the double median was
chosen as cut off for severe adverse outcome.
In 7 Swedish children under the age of 4 and 26 Danish
children under the age of 6, lung function data were not
available due to the low age of the patients. In these children,
lung function was assessed clinically and/or radiologically.
2.3. Microbiological diagnosis
Samples for respiratory secretion cultures were obtained
when the patient attended a routine outpatient visit.
Sampling, transport, and culturing were performed accord-
ing to routine procedures. For the Swedish patients,
colonization was defined according to European consensus,
i.e. three consecutive positive cultures [24]. All patients were
assisted by a physiotherapist in order to provide expectorate
for sputum culture. Non-sputum producers were considered
not colonized. For the Danish patients lower respiratory tract
secretions were obtained by coughing (sputum producers) or
endo-laryngeal suction, and sputum microbiology was
carried out. Infection was considered chronic, when an
organism had been cultured for 6 consecutive months or less
if there was a simultaneous increase in precipitating
antibodies against P. aeruginosa above normal level [25].
Among the not transplanted patients, 40% of the Swedish
patients, and 42% of the Danish patients were chronically
colonized with P. aeruginosa.2.4. ELISA for measurement of BPI-ANCA
Serum samples were drawn and analysed for BPI-ANCA
of the IgA and IgG isotypes. On analysing data, similar
results were found concerning IgG- and IgA-BPI-ANCA.
From now on, BPI-ANCA refers to the IgA isotype. Purified
BPI was obtained from Wieslab AB (Lund, Sweden), and
direct binding ELISAwas performed as previously described
[26]. In short, antigens were coated onto microtiter plates at a
concentration of 1 μg/ml in a bicarbonate buffer. Serum
samples were diluted 1/80 and incubated for 1 h. Bound
antibodies were detected using alkaline phosphatase-conju-
gated goat anti-human IgA (Eurodiagnostica, Malmö,
Sweden). BPI-ANCA was quantified from a calibrator
curve of serum that was serially diluted. The results were
expressed as arbitrary units (U/L). In each ELISA one
positive and one negative control were analysed. BPI-ANCA
is not normally present in serum at any age. To define a
positive cut-off level, 42 normal sera were analysed. From
the absorbance values in these normal sera +3SD, the
positive cut off level was determined to be 67 U/L. BPI-
ANCA has previously been analysed in a pediatric non-CF
population and the median value was found to be on the
same level as in adult blood donors (Dr L Dorlöchter,
Bergen, Norway, personal communication). A significant
change in the BPI-ANCA level was defined as a minimum
increase or decrease of 50% of the BPI-ANCA value.
2.5. Statistics
The Mann-Whitney test and the Kruskal-Wallis test were
used when applicable. When prognostic groups or genotype
groups were compared with respect to outcome, the exact
two-sided Chi-square test, the Chi-square test for trend or the
Chi-square test for independence was employed.
3. Results
3.1. BPI-ANCA as a predictor of poor prognosis
Forty adult patients from a previous cross-sectional study
were followed for a mean time of 5.7 years (range 1.2–8.9)
[9]. In the BPI-ANCA positive group, seven out of 25 patients
had required lung transplantation, one had died from CF lung
disease and seven had significant loss of lung function. In the
BPI-ANCA negative group one patient died and one patient
had significant loss of lung function. Thus, 15 patients out of
25 (54%) in the BPI-ANCA positive group had a severe
adverse outcome and in the BPI-ANCA negative group only
two patients out of 15 (11%) had an adverse outcome
( p=0.01).
Lung function at inclusion was, as expected, a strong
predictive factor for outcome. In patients with severe lung
damage 8/12 (67%) had a severe adverse outcome and in
patients with moderately reduced lung function 8/17 (47%)
demonstrated comparable progression. Only one out of
Table 2
Severe adverse outcome after 1.2–8.9 years in 40 patients stratified
according to lung function at inclusion
Lung function BPI-ANCA Severe adverse outcome
Severe lung damage Negative n=1 0/1⁎
Positive n=11 8/11 (72%)⁎
Moderate lung damage Negative n=7 1/7 (14%)⁎
Positive n=10 7/10 (70%)⁎
Normal lung function Negative n=7 1/7 (14%)
Positive n=4 0/4
⁎In patients with FEV1b80%, a positive level of BPI-ANCA was
significantly correlated to severe adverse outcome, p=0.03, the exact,
two-sided Chi squared test. Severe lung damage, FEV1b50%; Moderate
lung damage, FEV1 50–80%; Normal lung function, FEV1 N80%. BPI-
ANCA negative, b67 U/L; BPI-ANCA positive N67 U/L.
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pred N80%) at inclusion showed a severe adverse outcome
( p=0.006).
To decide whether BPI-ANCA provides independent
prognostic information, the patients were stratified according
to FEV1 at inclusion. Within the group of patients with
moderate lung damage, severe adverse outcome was
significantly overrepresented in BPI-ANCA-positive
patients ( p=0.05). The difference between BPI-ANCA-
positive and BPI-ANCA negative patients was still signif-
icant when the group of patients with severe lung damage
was included ( p=0.03, Table 2).
3.2. Serum levels of BPI-ANCA correlate to P. aeruginosa
colonization and decreased lung function
BPI-ANCA was mainly found in patients chronically
colonized with P. aeruginosa. In the Swedish P. aeruginosa-Fig. 1. BPI-ANCA according to lung function. The BPI-ANCA values are
shown on a logarithmized scale. All patients who were old enough to
perform lung function test and who were not lung transplanted were
included in the analysis. Levels of BPI-ANCA in serum of patients with
severe lung damage (FEV1%pred b50%), moderate lung damage (FEV1%
pred 50–80%) and preserved lung function (FEV1%pred N80%). Swedish
patients are shown with shaded boxes and Danish patients are shown with
open boxes. The dashed line indicates the positive cut off level (67 U/L). The
Kruskal-Wallis test was used on non-logarithmized values to compare the
median values.colonized patients, the median BPI-ANCA level was 98 U/L,
as compared to 11 U/L in patients without chronic colo-
nization ( pb0.0001); in the Danish patients the corre-
sponding levels were 68 U/L and 15 U/L ( pb0.0001).
Patients with severe lung damage had higher levels of BPI-
ANCA than patients with moderate lung damage, and
patients with preserved lung function were BPI-ANCA
negative with few exceptions (Fig. 1).
3.3. BPI-ANCA is formed in response to P. aeruginosa
colonization during disease course
To examine the development of BPI-ANCA over time and
its relation to colonization and disease progression, patients
were divided into groups according to age. As expected, the
percentages of P. aeruginosa-colonized patients and patients
with severe lung damage increased with age in both the
Swedish and the Danish cohort (Fig. 2). In the youngest
group, aged 0–5, no patient had severe lung damage and very
few were chronically colonized with P. aeruginosa. None of
these young children were BPI-ANCA positive. In the next
group, aged 6–11, a few patients were chronically colonized
by P. aeruginosa and had developed lung damage. A few
patients in this group were also positive for BPI-ANCA. TheFig. 2. (a) Swedish patients. ( b) Danish patients. The patients were divided
into age groups in order to create a fictive time scale. The lines indicate
percentages of patients who are chronically colonized with Pseudomonas
aeruginosa, patients with positive serum levels of BPI-ANCA and patients
with severe lung damage. The youngest groups contain patients below
5 years of age, and the oldest contain patients over the age of 36. Severe lung
damage was defined as forced expiratory volume in 1 s (FEV1) below 50%
of the predicted value or had undergone lung transplantation, positive BPI-
ANCA: N67 U/L.
Fig. 3. Serum levels of BPI-ANCA before and after lung transplantation in
seven patients. The dashed line indicates the positive cut off level for BPI-
ANCA (67 U/L).
232 M. Carlsson et al. / Journal of Cystic Fibrosis 6 (2007) 228–233percentage of BPI-ANCA-positive patients increased with
age. In the oldest group, with patients above the age of 36,
50% of the Swedish patients and 70% of the Danish
patients were BPI-ANCA positive. The frequency of BPI-
ANCA positive patients increased with age, parallel to that of
P. aeruginosa colonization in both the Swedish and Danish
cohort. The median percentage of P. aeruginosa colonized
patients who were BPI-ANCA positive was 68% (inter-
quartile range 53–78%).
3.4. Stability of BPI-ANCA levels on serial analyses
To study the variations in BPI-ANCA levels over time we
performed a short-time prospective study in the Swedish
patients. BPI-ANCA levels were measured in serum with an
interval of at least 6 months. All together 311 samples from
121 patients were analyzed. The BPI-ANCA levels were
found to be stable. Significant increases were only found in
11 patients. In all, only two patients who were not trans-
planted exhibited significant decreases of BPI-ANCA.
3.5. Decrease of BPI-ANCA following lung transplantation
In seven patients BPI-ANCA serum samples were
obtained before and after lung transplantation. All patients
were strongly BPI-ANCA positive (range 191–3894 U/L)
and were chronically colonized with P. aeruginosa prior to
the transplantation. Lung transplantation was successful in
the patients, and no rejection had occurred when the second
BPI-ANCA sample was drawn. At this time the serum levels
of BPI-ANCA had decreased (range 52–90%) in all patients
(Fig. 3).
4. Discussion
Tools for prediction of prognosis are important in CF.
When mild mutations are rare, as in the populations studied,
the prognostic value of the genotype becomes less important.
This study shows that the presence of BPI-ANCA is a
predictor of poor prognosis in the disease. The predictivevalue of BPI-ANCAwas strongest in patients with moderate
lung damage, a group of patients for which prognostic
information is particularly relevant. In those with severe lung
damage, the predictive value of negative BPI-ANCA is dif-
ficult to evaluate, due to the low number of patients.
The association between BPI-ANCA, P. aeruginosa
colonization and lung damage in CF was investigated in
366 CF patients in the age interval between 0.5 and 55 years.
The findings are consistent with earlier reports [5–10].
Patients with the most severe lung damage exhibited the
highest serum levels of BPI-ANCA and patients with normal
lung function most often had low or negative BPI-ANCA
levels (Fig. 1). Because of differences in definitions of
chronic P. aeruginosa colonization and in the collection of
lung function variables over time we decided to look at the
Swedish and the Danish patients as two independent cohorts.
The fact that the same results were found in both groups
shows that the findings are general, which adds credibility.
The prevalence of BPI-ANCA increased with age in
both cohorts, as did the prevalence of P. aeruginosa-colo-
nization and impaired lung function. The prevalence of lung
damage and BPI-ANCA was lower than the prevalence of
P. aeruginosa-colonization in most age groups. This
probably indicates that P. aeruginosa-colonization of the
airways precedes the generation of BPI-ANCA and the
development of lung damage. This has not previously been
shown and it leads us to speculate that a proportion of the
chronically colonized patients do not develop BPI-ANCA
due to variability between strains or other bacteria-related
factors (Fig. 2). On serial analysis, BPI-ANCA was mostly
found to be stable. As CF patients often carry the same strain
of P. aeruginosa for years, occasional rises in BPI-ANCA as
observed in the population might very well coincide with
acquisition of new strains [27]. To study if this is the case, a
large prospective study including recurrent extended micro-
biological analysis, frequent BPI-ANCA analysis and clini-
cal assessment would be needed.
All investigated patients who were lung transplanted, and
thereby received sterile lungs, showed a significant decrease
in BPI-ANCA levels. This finding indirectly supports the
hypothesis that BPI-ANCA in serum covariates with
colonization by harmful strains of P. aeruginosa. Interest-
ingly, one patient, who was lung transplanted before she was
included into our study, contracted chronic rejection and was
re-colonized with P. aeruginosa at the time of our study. At
the same time her serum levels of BPI-ANCA rose signi-
ficantly (data not shown). It has been proposed that the
decrease in BPI-ANCA following transplantation is due to
the immunosuppressive treatment. The BPI-ANCA levels of
the patients investigated in this study decreased by more than
50% after their lung transplantations. There is no immuno-
suppressive drug that is known either to cause such a
decrease of the total immunoglobulin level, or to selectively
suppress certain clones of B-cells. The immunosuppressive
treatment cannot therefore alone explain the substantial fall
in BPI-ANCA after lung transplantation. In the patient who
233M. Carlsson et al. / Journal of Cystic Fibrosis 6 (2007) 228–233contracted chronic rejection, the immunosuppressive treat-
ment was unchanged, and still her BPI-ANCA levels rose
significantly.
In conclusion we found that the presence of BPI-ANCA in
CF indicates poor prognosis. Furthermore, we have reason to
speculate that BPI-ANCA in CF distinguishes between
patients with apparently harmless colonization by
P. aeruginosa from patients with progressive lung disease
caused by the same species. Serum levels of BPI-ANCA
decrease after lung transplantation. The occurrence of BPI-
ANCA appears to follow colonization with harmful strains of
P. aeruginosa. We believe that BPI-ANCAwill prove to be an
important diagnostic tool in the care of patients with CF.
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